Most active New York Stock Exchange-traded stocks
AP - Wed Aug 20, 5:02PM CDT
NEW YORK (AP) — A look at New York Stock Exchange 10 most-active stocks at the close of trading:
Final Glance: Pharmaceuticals companies
AP - Wed Aug 20, 5:02PM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies were mixed at the close of trading:
Healthcare Enjoys Growth Trends: 3 Medical Stocks to Buy - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Aug 20, 3:27PM CDT
Favorable industry trends in the pharma and bio-tech space makes the healthcare sector a lucrative investment destination.
Baxter International Expands Dialyzers Facility in Alabama - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Aug 20, 2:10PM CDT
Baxter International (BAX) has been experiencing burgeoning demand for dialyzers across the globe as more people are getting inflicted by ESRD
Midday Glance: Pharmaceuticals companies
AP - Wed Aug 20, 12:50PM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies are mixed at 1 p.m.:
Early Glance: Pharmaceuticals companies
AP - Wed Aug 20, 11:22AM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies are mixed at 10 a.m.:
Expanding IBD Research Through Collaboration
PR Newswire - Wed Aug 20, 8:00AM CDT
The Crohn's & Colitis Foundation of America (CCFA) announces an agreement with Pfizer Inc.'s Centers for Therapeutic Innovation (CTI) to identify and support the potential development and translation of research in the area of inflammatory bowel disease (IBD). Capitalizing on CCFA's expertise in the field of IBD research and CTI's network of academic medical centers, the organizations will collaborate to drive promising translational research projects toward the clinic. The collaboration will initially involve the co-funding of research projects that focus on studying validated targets in Crohn's Disease and ulcerative colitis, which are the two most common types of IBD. This alliance represents CCFA's first-ever joint funding agreement with a pharmaceutical company.
Bristol-Myers Squibb and Pfizer to Present New Data on Eliquis(R) (apixaban) at the ESC Congress 2014
Business Wire - Wed Aug 20, 7:00AM CDT
--New global health economics and outcomes research (GHEOR) assessing Eliquis cost effectiveness and real-world comparative effectiveness research will also be presented
Pfizer Submits Palbociclib Marketing Application to the FDA - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Aug 19, 3:20PM CDT
Pfizer Inc. (PFE) announced that it has submitted the marketing application for its oncology candidate, palbociclib, to the FDA.
Pfizer files NDA of Palbociclib with US FDA for breast cancer
M2 - Tue Aug 19, 10:34AM CDT
Healthcare company Pfizer (NYSE
3 Reasons Pfizer Inc.'s Stock Could Rise
Sean Williams, The Motley Fool - Motley Fool - Tue Aug 19, 10:01AM CDT
Pfizer , arguably the preeminent pharmaceutical company in the world, continues to pump out billions in free cash flow annually, deliver delectable gross margins, and pay out an annual dividend that puts the S&P 500 average yield of 2% to...
Technical Updates, Drug Recommendations, and Upcoming Events - Research Reports on Gilead, Pfizer, AbbVie, Express Scripts and Humana
PR Newswire - Tue Aug 19, 8:20AM CDT
Today, Analysts Review released its research reports regarding Gilead Sciences, Inc. (NASDAQ: GILD), Pfizer Inc. (NYSE: PFE), AbbVie Inc. (NYSE: ABBV), Express Scripts Holding Company (NASDAQ: ESRX) and Humana Inc. (NYSE: HUM). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/5808-100free.
Sinopharm, Biostar, Lilly Rise on Medical Modernization in China
at The Street - Mon Aug 18, 1:11PM CDT
Pharmaceutical companies are profiting from China’s urban ailments and a growing appetite for western-style medicinal treatments
Pfizer (PFE) Breaks Through Resistance at $28.89
Comtex SmarTrend(R) - Mon Aug 18, 11:02AM CDT
Shares of Pfizer (NYSE
Global Antifungal Therapeutics Market 2014 Trends and Opportunities New Study Now Available at MarketReportsOnline.com
PRWeb - Mon Aug 18, 8:31AM CDT
The report titled "Global Antifungal Therapeutics Market: Trends and Opportunities (2014-2019)" provides an in-depth analysis of global antifungal therapeutics market with focus on antifungal drug classes - Polyenes, Azoles, Echinocandins and Allylamines. It provides broad coverage of these classes with detailed analysis of drugs and indications in respective classes. It also assesses the key opportunities and underlying trends in the market and outlines the factors that are and will be driving the growth of the industry in the forecasted period (2014-19). Further, key players of the industry such as Merck & Co., Inc., Pfizer Inc., Astellas Pharma Inc. and Noble Corporation SCYNEXIS, Inc. are also profiled in the report.
Premier Biotechnology & Anti-CTLA4
ACCESSWIRE - Mon Aug 18, 7:02AM CDT
Whitefish, MT / August 18, 2014 / Many forms of cancer are characterized by a lack of cellular apoptosis (e.g. cell death) and down-regulation of the immune system. In the case of the latter, cytotoxic T lymphocytes ("CTLs"